Pemvidutide for Alcohol-Associated Liver Disease

This study is conducted to explore the effectiveness and safety of a drug called pemvidutide in treating people with alcohol-associated liver disease (ALD). ALD is a condition where the liver is damaged due to excessive alcohol consumption, and finding effective treatments is crucial for improving the health and lives of those affected. Participants in this study include individuals diagnosed with ALD, and the results could potentially offer a new treatment option for managing this disease. Participants in this trial receive an injection of either pemvidutide or a placebo (an inactive substance) once a week. The study is designed to ensure that neither the participants nor the researchers know who receives the actual medication or the placebo, a method called double-blind, to prevent bias. The main goal is to assess how well pemvidutide works in treating ALD and to ensure it is safe for use. By comparing the results from both groups, researchers aim to determine the efficacy and safety of the treatment.